Transcode Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.63M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2024 Ended Mar 31, 2024 | Apr 5, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 16, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | After market close | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 1, 2023 | After market close | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | After market close | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 15, 2022 | After market close | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | Apr 1, 2022 | After market close | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 15, 2021 | After market close | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 23, 2021 | After market close | – | – | – |
Press releases
Announcements Transcode Therapeutics filed with the SEC
Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
Other events · EX-99.1 to Form 8-K
Before you invest in the securities of TransCode Therapeutics, Inc. (“TransCode” or the “Company”), you should read TransCode’s filings
Regulation FD disclosure · EX-99.1 to Form 8-K
Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
Other events · EX-99.1 to Form 8-K
TransCode Therapeutics Enters into Agreements for up to $20 Million
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free
Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TransCode Therapeutics Announces Publication of Preclinical Testing
Regulation FD disclosure · EX-99.1 to Form 8-K
TransCode Therapeutics and Quantum Leap Announce Submission of
Regulation FD disclosure · EX-99.1 to Form 8-K
TransCode Therapeutics Announces Publication of Preclinical Data
Regulation FD disclosure · EX-99.1 to Form 8-K
For the years ended December 31, 2024 and
Other events · EX-99.1 to Form 8-K/A
For the nine months ended September 30,
Other events · EX-99.2 to Form 8-K/A
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
Other events · EX-99.3 to Form 8-K/A
TransCode Expands Leadership with Appointment of Jack E. Stover to
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
TransCode Therapeutics and Quantum Leap Healthcare Collaborative
Regulation FD disclosure · EX-99.1 to Form 8-K
TransCode Therapeutics presents preliminary data
Other events · EX-99.1 to Form 8-K
TransCode Therapeutics, Inc. is developing TTX-MC138, an antisense
Other events · EX-99.2 to Form 8-K
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
E UNIQUE METASTATIC CANCER AND VACCINE IMMUNO - ONCOLOGY TREATMENT COMPANY TO REDEFINE CANCER CARE NASDAQ: RNAZ Exhibit 99.2
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
TransCode Therapeutics Announces Effective Date for
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Press Release: TransCode Therapeutics Announces 1-for-28 Reverse Stock
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Adjournment of Special Meeting and Information for Adjourned Special Meeting
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
BOSTON, February 25, 2025 (GLOBE NEWSWIRE)
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
Shareholder vote results · Other events · EX-99.1 to Form 8-K
TransCode Therapeutics Announces Safety Review Committee
Other events · EX-99.1 to Form 8-K
Nov. 27, 2024 -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company ™
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TransCode Therapeutics Announces 1-for-33 Reverse
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
TransCode Therapeutics Announces Effective Date
Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
TransCode Therapeutics, Inc. Announces Proposed Public Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
TransCode Therapeutics, Inc. Announces Pricing of Public
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Therapeutics Reports 2023 Results; Provides Business Update
Results of operations · EX-99.1 to Form 8-K
TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
Other events · EX-99.1 to Form 8-K
of $7.25 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
TransCode Therapeutics Announces Closing of
Material agreement · Other events · EX-99.2 to Form 8-K
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
Results of operations · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
TransCode Therapeutics Announces $1.2 Million Registered Direct
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
TransCode Therapeutics Announces Closing of
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
Results of operations · EX-99.1 to Form 8-K
TransCode Therapeutics Announces Preliminary Clinical
Other events · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $8 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
TransCode Therapeutics Announces Closing of $8.5 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K